Bayer AG ((BAYRY)), Bayer Ag (UK) ((GB:0P6S)) announced an update on their ongoing clinical study.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Bayer AG is conducting a clinical study titled A 6-month Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety and PK/PD of an age-and Body Weight-adjusted Oral Finerenone Regimen, in Addition to an ACEI or ARB, for the Treatment of Children, 6 Months to <18 Years of Age, With Chronic Kidney Disease and Proteinuria. The study aims to assess the effectiveness and safety of finerenone, a drug intended to improve kidney function in children with chronic kidney disease (CKD) and proteinuria, when used alongside existing treatments like ACE inhibitors or angiotensin receptor blockers.
The intervention being tested is finerenone (Kerendia, BAY94-8862), an experimental drug designed to control overactivation of the renin-angiotensin-aldosterone system (RAAS) in CKD patients. It is administered alongside standard treatments to determine if it can further reduce protein levels in urine compared to a placebo.
This interventional study follows a randomized, parallel assignment model with quadruple masking, meaning that participants, care providers, investigators, and outcomes assessors are unaware of the treatment allocations. The primary purpose is to evaluate treatment efficacy.
The study began on March 28, 2022, with recruitment currently ongoing. The primary completion date is set for June 24, 2025, which is also the last update date. These dates are crucial for tracking the study’s progress and anticipating results.
The outcome of this study could significantly impact Bayer’s market position, potentially enhancing investor confidence and stock performance if finerenone proves effective. This development may also influence the competitive landscape in the pharmaceutical industry, particularly in treatments for CKD.
The study is ongoing, and further details can be accessed on the ClinicalTrials portal.